Fertility Services Market Size, Share, Growth, and Industry Analysis, By Type (Male Infertility, Female Infertility), By Application (Fertility Clinics, Hospitals, Surgical Centers, Clinical Research Institutes), Regional Insights and Forecast to 2035

Fertility Services Market Overview

The global Fertility Services Market size estimated at USD 58683.11 million in 2026 and is projected to reach USD 335915.67 million by 2035, growing at a CAGR of 21.39% from 2026 to 2035.

The global fertility services market represents one of the most dynamic and rapidly expanding segments within modern healthcare. As of 2024, the market reached a valuation of approximately 46.1 billion USD, fueled by an unprecedented convergence of biological, social, and technological forces redefining how humanity approaches reproduction. Globally, more than 186 million people are affected by infertility, representing nearly 15% of couples of reproductive age worldwide. The fertility services landscape spans in-vitro fertilization (IVF), intrauterine insemination (IUI), intracytoplasmic sperm injection (ICSI), surrogacy, cryopreservation, and fertility diagnostics. Fertility clinics account for 80% of all global service delivery, making them the structurally dominant providers of integrated care. Over 2.5 million IVF cycles are performed globally each year, and advancements in AI-driven embryo selection, preimplantation genetic testing (PGT), and vitrification have elevated live-birth success rates across all patient age groups. The treatment segment commanded 65.33% of total market share in 2023, underscoring that active clinical intervention remains the core economic driver of this sector.

In the United States, infertility affects approximately 10% of women aged 15 to 44, translating to nearly 6.1 million women who struggle to conceive or carry a pregnancy to term. Male factor infertility accounts for 30% of all infertility cases in the country, with roughly 9% of men experiencing fertility challenges. According to the CDC's Fertility Clinic Success Rates Report, 238,126 patients underwent 413,776 ART cycles at 453 reporting clinics, resulting in 91,906 live births and 97,128 live birth infants. IVF success rates for women under 35 now reach approximately 55% per fresh cycle, an improvement of more than 266% since IVF was first introduced clinically. The IVF segment holds approximately 60% of the US infertility treatment market share, supported by rising insurance coverage, employer fertility benefits, and expanding public awareness. Egg freezing cycles surged from only 475 cases in 2009 to over 29,000 in 2022 — a 61-fold increase — reflecting a fundamental shift in how Americans approach reproductive planning. Only 19 US states mandate insurance coverage for IVF procedures as of 2025, meaning the majority of patients still face significant out-of-pocket expenditures.

• 

  Download Free sample to learn more about this report.

Key Findings

• Key Market Driver: Rising global infertility rates are the primary growth engine, with approximately 48% of fertility specialists reporting a measurable increase in patient volume over the past 3 years, and over 65% of new patients citing delayed parenthood as the primary reason for seeking treatment.
• Major Market Restraint: High out-of-pocket costs remain the most significant barrier to treatment access, with 58% of individuals who need fertility care reporting they cannot afford it, and only 19 US states mandating insurance coverage for IVF procedures as of 2025.
• Emerging Trends: AI-powered embryo selection tools now demonstrate approximately 69% accuracy in predicting chromosomal normalcy, and approximately 42% of fertility clinics globally had integrated some form of artificial intelligence into IVF laboratory protocols by 2024.
• Regional Leadership: Europe led the global fertility services market with a 35.74% share in 2023, while Asia-Pacific is the fastest-growing region with over 48% of new clinic openings occurring there between 2022 and 2024.
• Competitive Landscape: The global fertility services market is moderately fragmented, with the top 5 companies controlling approximately 30% of total market share, while over 50 identified key service providers operate across all major regions globally.
• Market Segmentation: Female infertility held 61.62% of the fertility treatment market share in 2025, while the fertility clinics segment commanded 80% of total service delivery, far surpassing hospitals and surgical centers in both patient volume and procedure count.
• Recent Development: In January 2025, Merck KGaA launched a next-generation hormone therapy using advanced recombinant technology to improve ovarian stimulation during IVF, and in October 2024 CooperSurgical unveiled an AI-powered embryo selection system integrating time-lapse imaging to increase implantation success rates.

Fertility Services Market Latest Trends

The fertility services market is undergoing a profound technological and structural transformation driven by digitalization, personalization, and global demographic shifts. One of the most impactful trends reshaping the sector is the integration of artificial intelligence into IVF laboratory workflows. AI-based embryo grading systems validated in studies published in the Journal of Assisted Reproductive Genetics in February 2024 demonstrated clinically superior accuracy in selecting viable embryos compared to conventional manual assessment. Approximately 42% of fertility clinics globally adopted AI-assisted embryo selection protocols by 2024, and adoption is expected to surpass 65% by 2027.

Cryopreservation technologies are experiencing accelerated uptake, particularly vitrification, which now achieves oocyte survival rates exceeding 97% and has become the global standard for egg and embryo banking. Egg freezing cycles in the United States grew 61-fold between 2009 and 2022, with over 29,000 cycles recorded in 2022, closely linked to employer-sponsored fertility benefits. Over 40% of Fortune 500 companies now offer some form of egg freezing or fertility preservation coverage for employees.

Telehealth fertility consultations are expanding access to specialist reproductive care in underserved markets. The male infertility segment is gaining clinical recognition at an accelerating pace, supported by AI-driven semen analysis, smartphone-based diagnostics, and targeted investment. ReproNovo raised 65 million USD in Series A funding in May 2025 to advance clinical trials specifically targeting male infertility. Preimplantation genetic testing (PGT) adoption is rising sharply, with studies confirming that 84.2% of tested blastocysts showed euploidy, significantly reducing miscarriage risk. Meanwhile, the donor embryo program achieves a 40.6% live birth rate per IVF cycle in the US, demonstrating consistent clinical reliability that continues to expand patient uptake.

Fertility Services Market Dynamics

DRIVER

"Rising Global Infertility Rates and Delayed Parenthood Trends."

Infertility now affects an estimated 186 million people globally, representing 15% of couples of reproductive age. In the United States, over 10% of women aged 15 to 45 face fertility challenges, while male factor infertility contributes to approximately 30% of all diagnosed cases nationally. The median age of first-time mothers has risen consistently across developed economies due to career prioritization, extended education, and delayed marriage. In the US, 12% of couples under 30 experience difficulty conceiving, and this percentage rises significantly when women are between 30 and 40. PCOS, affecting 5% to 10% of women of childbearing age, is responsible for 90% of all anovulation-related infertility cases, creating a large, continuously replenishing patient population that fuels clinic utilization. Environmental factors including endocrine-disrupting chemical exposure, rising obesity rates, and sedentary lifestyles compound the global infertility burden. IVF cycles are increasing at approximately 6% annually globally, driven by underlying demand combined with improving clinical outcomes. Women under 35 now achieve live birth rates of nearly 55% per fresh IVF cycle, clinical outcomes that are convincing larger proportions of infertile couples to pursue assisted reproductive technologies with confidence.

RESTRAINT

"Prohibitively High Cost of Fertility Treatments and Limited Insurance Coverage."

Despite growing demand, the financial burden of fertility treatment remains the most formidable barrier preventing broad market penetration. In the United States, a single IVF cycle costs an average of 12,000 to 15,000 USD before medications, with total costs often reaching 25,000 USD or more per attempt. Only 19 US states mandate insurance coverage for IVF procedures as of 2025. Globally, 58% of individuals who require fertility treatment report that cost is the primary reason they do not pursue it. In developing economies, the price-to-income ratio for a single IVF cycle can exceed 10 times the average monthly household income, effectively excluding the majority of the population from accessing care. Even in markets with partial reimbursement, cumulative costs across multiple cycles — which more than 50% of patients require — create significant financial strain. The absence of standardized global reimbursement frameworks limits market penetration across the segments representing the largest pools of potential patients.

OPPORTUNITY

"Expanding AI Integration and Personalized Fertility Treatment Platforms."

The convergence of artificial intelligence, genomics, and precision medicine is creating extraordinary growth opportunities within fertility services. AI embryo selection tools predict chromosomally normal embryos with approximately 69% accuracy using image analysis and maternal age data, reducing the need for invasive genetic testing while improving outcomes. Personalized ovarian stimulation protocols based on individual genetic profiles and hormonal biomarkers represent a next clinical frontier, promising improved outcomes with fewer side effects. Overture Life secured 20.6 million USD in April 2025 to accelerate IVF laboratory automation. The fertility diagnostics segment presents significant opportunity, as AI-driven semen analysis devices and smartphone-based platforms democratize access to initial fertility assessment. The fertility preservation market for cancer patients is expanding rapidly, as oncology treatment protocols increasingly incorporate fertility preservation counseling as standard of care. These intersecting developments are transforming fertility services from episodic treatment events into continuous, data-driven care journeys that generate sustained patient engagement and lifetime service value.

CHALLENGES

"Ethical, Regulatory, and Social Complexity Surrounding Assisted Reproduction."

The fertility services market operates within a uniquely complex regulatory and ethical environment. Regulatory frameworks governing IVF, surrogacy, egg donation, and genetic testing vary significantly across jurisdictions, creating compliance burdens for multinational clinic operators. Ethical debates around preimplantation genetic diagnosis, embryo selection, and the commercialization of donor programs generate regulatory uncertainty that delays product approvals and market entry. In several European countries, restrictions on the number of embryos transferable per cycle directly affect clinical protocols and outcomes. Patients undergoing multiple failed IVF cycles experience psychological distress comparable to cancer diagnoses, contributing to dropout rates between treatment attempts. Data privacy concerns related to patient genetic information in AI training datasets are emerging as a regulatory flashpoint. A shortage of trained reproductive endocrinologists and embryologists in key growth markets, particularly across Africa and Southeast Asia, limits market expansion even where demand clearly exists.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

The fertility services market is segmented by type into male infertility and female infertility, and by application into fertility clinics, hospitals, surgical centers, and clinical research institutes. The treatment segment held 65.33% of total market share in 2023, while fertility clinics dominate as the preferred care setting with 80% of all global service delivery. Each segment demonstrates distinct dynamics and technological requirements that collectively define the market's structural architecture.

By Types

Male Infertility : The male infertility segment accounts for approximately 38% of the global fertility treatment market, reflecting growing clinical recognition of male factor contributions. Studies confirm that male factors contribute to roughly one-third of all infertility cases globally, with a further third involving simultaneous male and female contributions. Conditions including low sperm count, reduced motility, and abnormal morphology account for the majority of diagnoses, with azoospermia affecting approximately 1% of all men. ICSI, which involves direct injection of a single sperm into an egg, has become the standard treatment for severe male factor infertility. AI-powered semen analysis platforms using deep learning are improving diagnostic accuracy and enabling precise treatment stratification. The United States male infertility market is projected to reach 6.62 billion USD by 2033, with North America holding a 37% share of this specific segment. Posterity Health closed 13 million USD in February 2025 for comprehensive male fertility care expansion, while Ferring Pharmaceuticals launched a digital Male Fertility program offering AI-assisted confidential assessments.

Female Infertility : Female infertility represents the dominant segment, commanding 61.62% of total fertility treatment market share in 2025. PCOS affects 5% to 10% of women of reproductive age worldwide and accounts for 90% of anovulatory infertility cases, creating the largest addressable patient subgroup in fertility medicine. A 25-year-old woman has an 18% chance of conceiving per cycle, while this drops to only 7% by age 40, driving demand for early intervention including egg cryopreservation. IVF success rates for women under 35 now approach 55% per fresh cycle, and frozen embryo transfer (FET) adoption is rising given its superior endometrial preparation outcomes. The female infertility segment encompasses hormonal stimulation, egg retrieval, IVF, embryo transfer, surrogacy, and fertility preservation across the full patient care continuum. Merck KGaA's January 2025 launch of an advanced recombinant hormone therapy directly targeting ovarian stimulation outcomes reflects the scale of pharmaceutical investment directed at this dominant segment.

By Applications

Fertility Clinics : Fertility clinics command 80% of total service delivery globally and represent the dominant application segment. Their specialized infrastructure — embryology laboratories, cryostorage facilities, andrology units, and genetic testing capabilities — makes them uniquely positioned to deliver the full spectrum of ART procedures. In the United States, 453 clinics reported data to the CDC, collectively performing 413,776 ART cycles yielding 91,906 live births. Rapid consolidation through mergers and acquisitions is reshaping the segment, with networks including IVI RMA, Spring Fertility, and Kindbody expanding aggressively. Kindbody acquired Vios Fertility Institute in Q2 2024, while Spring Fertility opened its first Canadian clinic in Toronto in Q2 2025, exemplifying the geographic expansion strategies driving clinic network growth.

Hospitals : Hospitals represent the second-largest application segment, relevant for complex cases integrating reproductive medicine with oncology or surgical care. The hospital segment holds approximately 20% of ART cycle delivery in the United States. European national health systems, which fund defined IVF cycles per patient, rely heavily on hospital-based programs, making this segment structurally important in publicly funded healthcare markets.

Surgical Centers : Surgical centers are experiencing the fastest growth among all application segments, driven by the shift toward outpatient care models, reduced facility costs, and improved minimally invasive surgical techniques. Fertility and surgical centers combined held 54.7% of the global IVF market share in 2024, reflecting their central procedural role. The segment is expanding as fertility services increasingly integrate reproductive endocrinology with surgical management of conditions such as endometriosis and varicocele, creating demand for dedicated outpatient surgical fertility facilities.

Clinical Research Institutes

Clinical research institutes generate the clinical evidence underpinning commercial fertility service protocols. This segment encompasses academic medical centers, university-affiliated reproductive biology departments, and independent research organizations. AI-based embryo grading research published in the Journal of Assisted Reproduction and Genetics in February 2024 demonstrated superior embryo selection accuracy versus conventional methods, directly accelerating commercial product development. ReproNovo's 65 million USD Series A reflects the commercial importance of research institute collaboration in advancing fertility medicine.

• 

  Download Free sampleto learn more about this report.

Fertility Services Market Regional Outlook

The fertility services market exhibits distinct regional dynamics shaped by healthcare infrastructure maturity, regulatory frameworks, cultural attitudes toward assisted reproduction, demographic profiles, and reimbursement policies. Europe and North America represent the most commercially mature markets, while Asia-Pacific is the fastest-growing region. The Middle East and Africa are emerging markets where increasing healthcare investment and rising awareness are gradually building market foundations.

North America

North America holds approximately 24.9% of the global fertility services market, with the United States as the primary growth engine. The US IVF market was valued at approximately 5.28 billion USD in 2023, and the broader US fertility market is projected to surpass 19.72 billion USD by 2034. Over 10% of women aged 15 to 44 face infertility challenges, and 238,126 patients underwent 413,776 ART cycles at 453 accredited clinics in a single reporting year, producing 91,906 live births. The IVF segment commands approximately 60% of the US infertility treatment market, backed by expanding insurance mandate coverage across 19 states. Egg freezing cycles grew from 475 in 2009 to over 29,000 in 2022, accelerated by employer fertility benefits. Investment in North American fertility startups remains robust, with Posterity Health, Overture Life, and Illumicell AI raising tens of millions of dollars in 2024 and 2025.

Europe

Europe leads the global fertility services market with approximately 35.74% of total market share in 2023. Germany holds the largest national share within the region, followed by the United Kingdom, France, Spain, and Italy. Multiple EU member states fund between 3 and 6 IVF cycles per patient through national health insurance. The European IVF market was valued at approximately 12.20 billion USD in 2025. Medical tourism drives significant cross-border patient flows, with patients from Eastern Europe and the Middle East traveling to Spain, Czech Republic, and Greece for donor programs. Vitrolife AB completed the acquisition of a European microfluidic sperm-sorting startup in May 2025, reinforcing regional technology leadership. Norway is projected to register the fastest national growth rate within Europe through 2030.

Asia-Pacific

Asia-Pacific is the fastest-growing regional market in global fertility services, with approximately 42.6% of total revenue in 2025, driven by China's and India's population scale. China recorded its lowest birth rate since national records began in 2022, prompting government policy shifts expanding ART access. Government agencies in Maharashtra, India launched fertility treatment access initiatives in 2024. Japan increased IVF subsidies in response to one of the world's lowest national fertility rates. India is the fastest-growing individual country market within Asia-Pacific, driven by competitive pricing and a large skilled specialist workforce that attracts international medical tourism. Over 48% of new fertility clinic openings globally between 2022 and 2024 occurred in Asia-Pacific.

Middle East & Africa

The Middle East and Africa fertility services market is in an earlier development stage but demonstrating consistent growth momentum. The UAE and Saudi Arabia are the primary commercial drivers, with the UAE positioned as a regional hub attracting patients from the Gulf Cooperation Council, North Africa, and South Asia. South Africa leads the African segment, supported by a growing network of fertility clinics in major urban centers. Islamic jurisprudence generally permits IVF using the couple's own gametes, supporting social acceptance in Muslim-majority markets. Private insurance plans across several GCC states now include fertility treatment coverage, and broader healthcare infrastructure investment is creating capacity to absorb growing demand across the region.

List of Top Fertility Services Market Companies

• Instituto Bernabeu SL
• The Cooper Companies Inc.
• Merck KGaA
• Monash IVF Group Ltd.
• CRITEX GmbH
• Vitrolife AB
• Esco Micro Pte. Ltd
• Anecova SA
• INVO Bioscience Inc
• Virtus Health Ltd.

List of Top 2 Companies Market Share

• The Cooper Companies Inc. (CooperSurgical): CooperSurgical commands an estimated 12% to 15% share of the global fertility technology and devices market, supported by a portfolio exceeding 600 individual products used in IVF and reproductive procedures across more than 100 countries. The company's October 2024 launch of an AI-powered time-lapse embryo selection system, combined with the September 2025 acquisition of a male fertility diagnostics firm specializing in AI-driven sperm analysis, further consolidated its market leadership position. CooperSurgical's scale, breadth, and continuous technology investment make it the dominant commercial force in fertility technology globally.
• Vitrolife AB: Vitrolife AB, headquartered in Gothenburg, Sweden, holds an estimated 10% to 12% share of the global IVF equipment and media market. The company's Embryoscope time-lapse incubation system is deployed in over 100 countries and has become a standard technology in leading IVF laboratories worldwide. Vitrolife's May 2025 acquisition of a European microfluidic sperm-sorting startup reinforced its strategic expansion into male infertility technology. Consistent R&D investment — representing a significant proportion of annual operating expenditure — underpins Vitrolife's position as the leading European fertility technology innovator.

Investment Analysis and Opportunities

The fertility services market is attracting substantial investment from venture capital, private equity, and strategic acquirers. ReproNovo secured 65 million USD in Series A funding in May 2025 for Phase 2 trials targeting male infertility and embryo implantation. Overture Life raised 20.6 million USD in April 2025 to accelerate IVF laboratory automation. Posterity Health closed 13 million USD in February 2025 for male fertility care expansion. Illumicell AI raised 2 million USD in pre-seed funding for a portable AI-powered fertility fluid analysis scanner.

Private equity consolidation is reshaping the clinic landscape, with networks including Kindbody, Spring Fertility, and IVI RMA acquiring independent clinics and expanding geographically. The US fertility market, projected to reach 19.72 billion USD by 2034, represents an enormous opportunity for operators pursuing scale efficiencies. Strategic M&A is intensifying: CooperSurgical acquired a male fertility diagnostics firm in September 2025, Vitrolife acquired a microfluidic sperm-sorting startup in May 2025, Merck KGaA acquired a reproductive genetics company in February 2025, and Irvine Scientific acquired a reproductive media manufacturer in December 2024. Fertility-focused AI and digital health platforms attract disproportionate venture interest due to their scalability and potential to reduce per-procedure costs while improving outcomes.

New Product Development

Innovation in the fertility services market is advancing at a pace that is simultaneously transforming clinical outcomes and commercial dynamics. The most impactful area of new product development is artificial intelligence applied to embryo selection. AI algorithms trained on millions of embryo images can now predict chromosomal normalcy with approximately 69% accuracy using non-invasive image analysis, reducing clinical dependence on biopsy-based PGT in select cases. CooperSurgical's next-generation time-lapse embryo imaging system, launched in Q3 2024, integrates AI-driven developmental scoring with continuous environmental monitoring to optimize embryo selection in real time.

Merck KGaA's January 2025 hormone therapy launch using advanced recombinant technology enhances ovarian stimulation while reducing side effects associated with conventional gonadotropin protocols, representing a significant advance in fertility pharmacology. SpOvum released ARTGPT in November 2024, an AI-powered platform streamlining patient interaction, clinical decision support, and workflow management in fertility clinics. Microfluidic sperm-sorting devices isolating motile sperm with minimal physiological stress are demonstrating improved fertilization outcomes in male factor cases, with Vitrolife's acquisition of a sperm-sorting startup in May 2025 bringing this technology to commercial scale. In cryopreservation, advances in vitrification media have achieved oocyte survival rates exceeding 97%, making egg banking a clinically reliable reproductive option that is driving sustained consumer adoption across both fertility preservation and donor programs.

Five Recent Developments (2023–2025)

1. Merck KGaA — January 2025: Merck launched a next-generation fertility hormone therapy leveraging advanced recombinant technology to improve ovarian stimulation quality during IVF. The therapy enhances egg maturation efficiency while reducing the side effect profile versus conventional hormone protocols, representing a meaningful advance in pharmaceutical-driven fertility care.
2. CooperSurgical — October 2024: At the ASRM 2024 annual conference, CooperSurgical unveiled an AI-powered embryo selection system using time-lapse imaging and AI algorithms to analyze embryo developmental patterns and optimize implantation success rates, representing a new generation of real-time AI-scored embryo monitoring technology.
3. Vitrolife AB — May 2025: Vitrolife completed the acquisition of a European fertility technology startup specializing in microfluidic-based sperm sorting solutions, expanding its product portfolio into the high-growth male infertility technology segment and strengthening its end-to-end IVF laboratory offering.
4. ReproNovo — May 2025: ReproNovo secured 65 million USD in Series A funding led by Jeito Capital to advance Phase 2 trials of RPN-001 targeting male infertility and RPN-002 targeting adenomyosis and embryo implantation enhancement, one of the largest single fertility pharmaceutical investments of 2025.
5. Kindbody — Q2 2024: Kindbody completed the acquisition of Vios Fertility Institute, significantly expanding its national US clinic network and patient base, exemplifying the accelerating consolidation trend in which well-capitalized fertility networks acquire established independent clinics to build geographically comprehensive service platforms.

Report Coverage of Fertility Services Market

This research coverage of the fertility services market encompasses rigorous, multi-layered analysis spanning market sizing, segmentation, competitive intelligence, regional performance, and emerging trend tracking. The report covers IVF, ICSI, IUI, surrogacy, cryopreservation, and fertility diagnostics, with quantitative data derived from procedure volume tracking and treatment outcome databases globally. Coverage extends to 50 identified fertility service providers and technology manufacturers representing 70% to 75% of global market share in 2024.

Segmentation analysis is structured across type, application, and geography, covering 17 key national markets including the United States, Germany, United Kingdom, China, India, Japan, South Korea, Australia, Saudi Arabia, and UAE. The competitive landscape profiles The Cooper Companies Inc., Vitrolife AB, Merck KGaA, Monash IVF Group, and Instituto Bernabeu SL among others. Investment and M&A activity is tracked from 2023 through 2025. Historical data spans 2019 through 2024, with core segment forecasts extending through 2033. The report documents 5 major product development milestones from 2023 to 2025 that have materially shaped market dynamics, delivering actionable intelligence for clinical, commercial, and investment decision-making.